Novavax (NVAX) Long-Term Investments (2012 - 2013)

Novavax (NVAX) recorded quarterly Long-Term Investments of $1.1 million in Q1 2013, down 82.08% quarter-over-quarter from $6.2 million in Q4 2012.

Novavax (NVAX) Long-Term Investments (2012 - 2013) Analysis & Trends

Novavax's Long-Term Investments history runs 2 years deep, the most recent figure standing at $1.1 million for Q1 2013.

In Q1 2013, Long-Term Investments changed N/A year-over-year to $1.1 million; the TTM figure through Mar 2013 stood at $1.1 million (changed N/A YoY), while the FY2012 annual figure was $6.2 million, changed N/A from the prior year.
Long-Term Investments was $1.1 million for Q1 2013 at Novavax, down from $6.2 million in the prior quarter.
In the past five years, Long-Term Investments ranged from a high of $6.2 million in Q4 2012 to a low of $1.1 million in Q1 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	5.17 Mn
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	5.75 Bn
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Novavax	1.49 Bn	931.98 Mn	108.82 Mn	-

Download Data

Date	Value
Mar 31, 2013	1.12 Mn
Dec 31, 2012	6.23 Mn